Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults

被引：81

作者：

Moorthy, VS

Pinder, M

Reece, WHH

Watkins, K

Atabani, S

Hannan, C

Bojang, K

McAdam, KPWJ

Schneider, J

Gilbert, S

Hill, AVS

机构：

[1] MRC Labs, Banjul, Gambia

[2] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England

来源：

JOURNAL OF INFECTIOUS DISEASES | 2003年 / 188卷 / 08期

基金：

英国惠康基金;

关键词：

D O I：

10.1086/378515

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The present study is an investigation of the safety and immunogenicity of DNA and modified vaccinia virus Ankara (MVA) candidate vaccines, each encoding the malaria DNA sequence multiple epitope-thrombospondin related adhesion protein (ME-TRAP), against Plasmodium falciparum. DNA ME-TRAP and MVA ME-TRAP are safe and immunogenic for effector and memory T cell induction. MVA ME-TRAP, with or without prior DNA ME-TRAP immunization, was more immunogenic and more cross-reactive in malaria-exposed individuals than in malaria-naive individuals, a finding suggesting that recombinant MVA vaccines are particularly promising for the development of a malaria vaccine for exposed populations. Both CD4(+) and CD8(+) T cells were induced by these vaccines.

引用

页码：1239 / 1244

页数：6

共 20 条

[1] Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].